Cutaneous Melanoma Clinical Trials in New York, New York

6 studies are recruiting for cutaneous melanoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

   The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   57 in total

   Run by

   Guardant Health, Inc.

   See if you can join NCT05059444 on ClinicalTrials.gov

2. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

   This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Medical Center - Herbert Irving Pavilion, New York, New York

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT03947385 on ClinicalTrials.gov

3. ACTengine® IMA203 Combined With mRNA-4203

   This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   4 in total

   Run by

   Immatics US, Inc.

   See if you can join NCT06946225 on ClinicalTrials.gov

4. A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

   KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, r…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Weill Cornell Medicine-New York-Presbyterian Hospital, New York, New York

   Locations

   15 in total

   Run by

   Krystal Biotech, Inc.

   See if you can join NCT05970497 on ClinicalTrials.gov

5. A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

   This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Locations

   13 in total

   Run by

   GV20 Therapeutics

   See if you can join NCT05669430 on ClinicalTrials.gov

6. A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan-Kettering Cancer Center, New York, New York

   Locations

   11 in total

   Run by

   GI Innovation, Inc.

   See if you can join NCT05824975 on ClinicalTrials.gov